Literature DB >> 23284065

Metabolic changes in DYT11 myoclonus-dystonia.

Maren Carbon1, Deborah Raymond, Laurie Ozelius, Rachel Saunders-Pullman, Steven Frucht, Vijay Dhawan, Susan Bressman, David Eidelberg.   

Abstract

OBJECTIVE: To identify brain regions with metabolic changes in DYT11 myoclonus-dystonia (DYT11-MD) relative to control subjects and to compare metabolic abnormalities in DYT11-MD with those found in other forms of hereditary dystonia and in posthypoxic myoclonus.
METHODS: [(18)F]-fluorodeoxyglucose PET was performed in 6 subjects with DYT11-MD (age 30.5 ± 10.1 years) and in 6 nonmanifesting DYT11 mutation carriers (NM-DYT11; age 59.1 ± 8.9 years) representing the parental generation of the affected individuals. These data were compared to scan data from age-matched healthy control subjects using voxel-based whole brain searches and group differences were considered significant at p < 0.05 (corrected, statistical parametric mapping). As a secondary analysis, overlapping abnormalities were identified by comparisons to hereditary dystonias (DYT1, DYT6, dopa-responsive dystonia) and to posthypoxic myoclonus.
RESULTS: We found significant DYT11 genotype-specific metabolic increases in the inferior pons and in the posterior thalamus as well as reductions in the ventromedial prefrontal cortex. Significant phenotype-related increases were present in the parasagittal cerebellum. This latter abnormality was shared with posthypoxic myoclonus, but not with other forms of dystonia. By contrast, all dystonia cohorts exhibited significant metabolic increases in the superior parietal lobule.
CONCLUSIONS: The findings are consistent with a subcortical myoclonus generator in DYT11-MD, likely involving the cerebellum. By contrast, subtle increases in the superior parietal cortex relate to the additional presence of dystonic symptoms. Although reduced penetrance in DYT11-MD has been attributed to the maternal imprinting epsilon-sarcoglycan mutations, NM-DYT11 carriers showed significant metabolic abnormalities that are not explained by this genetic model.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23284065      PMCID: PMC3589244          DOI: 10.1212/WNL.0b013e31827f0798

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  Complex movements evoked by microstimulation of the ventral intraparietal area.

Authors:  Dylan F Cooke; Charlotte S R Taylor; Tirin Moore; Michael S A Graziano
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

2.  Clinical characteristics and topography of lesions in movement disorders due to thalamic lesions.

Authors:  S Lehéricy; S Grand; P Pollak; F Poupon; J F Le Bas; P Limousin; P Jedynak; C Marsault; Y Agid; M Vidailhet
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

3.  Increased risk for recurrent major depression in DYT1 dystonia mutation carriers.

Authors:  G A Heiman; R Ottman; R J Saunders-Pullman; L J Ozelius; N J Risch; S B Bressman
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

4.  Regional metabolism in primary torsion dystonia: effects of penetrance and genotype.

Authors:  M Carbon; S Su; V Dhawan; D Raymond; S Bressman; D Eidelberg
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

5.  Identification and characterization of epsilon-sarcoglycans in the central nervous system.

Authors:  Akiyo Nishiyama; Takeshi Endo; Shin'ichi Takeda; Michihiro Imamura
Journal:  Brain Res Mol Brain Res       Date:  2004-06-18

6.  Blink reflex studies in focal dystonias: enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis.

Authors:  E Tolosa; L Montserrat; A Bayes
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

7.  Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia.

Authors:  Birgitt Müller; Katja Hedrich; Norman Kock; Natasa Dragasevic; Marina Svetel; Jennifer Garrels; Olfert Landt; Matthias Nitschke; Peter P Pramstaller; Wolf Reik; Eberhard Schwinger; Jürgen Sperner; Laurie Ozelius; Vladimir Kostic; Christine Klein
Journal:  Am J Hum Genet       Date:  2002-11-20       Impact factor: 11.025

8.  Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.

Authors:  T Taniguchi; M J Sullivan; O Ogawa; A E Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

9.  Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan.

Authors:  Jianfeng Xiao; Mark S LeDoux
Journal:  Brain Res Mol Brain Res       Date:  2003-11-26

Review 10.  Expression of imprinted genes in human preimplantation development.

Authors:  M Monk; A Salpekar
Journal:  Mol Cell Endocrinol       Date:  2001-10-22       Impact factor: 4.102

View more
  25 in total

1.  Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia.

Authors:  Vikram G Shakkottai; Amit Batla; Kailash Bhatia; William T Dauer; Christian Dresel; Martin Niethammer; David Eidelberg; Robert S Raike; Yoland Smith; H A Jinnah; Ellen J Hess; Sabine Meunier; Mark Hallett; Rachel Fremont; Kamran Khodakhah; Mark S LeDoux; Traian Popa; Cécile Gallea; Stéphane Lehericy; Andreea C Bostan; Peter L Strick
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

Review 2.  It's not just the basal ganglia: Cerebellum as a target for dystonia therapeutics.

Authors:  Ambika Tewari; Rachel Fremont; Kamran Khodakhah
Journal:  Mov Disord       Date:  2017-08-26       Impact factor: 10.338

3.  Treatment of myoclonus-dystonia syndrome with tetrabenazine.

Authors:  Angelo Y Luciano; H A Jinnah; Ronald F Pfeiffer; Daniel D Truong; Martha A Nance; Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2014-10-05       Impact factor: 4.891

4.  Aberrant Purkinje cell activity is the cause of dystonia in a shRNA-based mouse model of Rapid Onset Dystonia-Parkinsonism.

Authors:  Rachel Fremont; Ambika Tewari; Kamran Khodakhah
Journal:  Neurobiol Dis       Date:  2015-06-17       Impact factor: 5.996

Review 5.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

Review 6.  Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders.

Authors:  Cecilia Peralta; Federico Biafore; Tamara Soto Depetris; Maria Bastianello
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-29       Impact factor: 5.081

7.  Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation.

Authors:  Kristoffer Haugarvoll; Charalampos Tzoulis; Gia T Tran; Bjørn Karlsen; Bernt A Engelsen; Per M Knappskog; Laurence A Bindoff
Journal:  J Neurol       Date:  2013-12-03       Impact factor: 4.849

8.  Abnormal high-frequency burst firing of cerebellar neurons in rapid-onset dystonia-parkinsonism.

Authors:  Rachel Fremont; D Paola Calderon; Sara Maleki; Kamran Khodakhah
Journal:  J Neurosci       Date:  2014-08-27       Impact factor: 6.167

9.  Deep brain stimulation for myoclonus dystonia syndrome: a meta-analysis with individual patient data.

Authors:  Xin Wang; Xinguang Yu
Journal:  Neurosurg Rev       Date:  2020-01-03       Impact factor: 3.042

Review 10.  ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene.

Authors:  Ana Cazurro-Gutiérrez; Anna Marcé-Grau; Marta Correa-Vela; Ainara Salazar; María I Vanegas; Alfons Macaya; Àlex Bayés; Belén Pérez-Dueñas
Journal:  Mol Neurobiol       Date:  2021-04-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.